A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023
Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q. | April 25, 2023